Tesetaxel
Tesetaxel is an orally administered taxane being investigated as a chemotherapy agent for various types of cancer, including breast cancer,[1] gastric cancer,[2] colorectal cancer,[3] and other solid tumors.[4] It differs from other members of the taxane class (e.g. paclitaxel or docetaxel) in that it is administered orally, not intravenously.[5]
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C46H60FN3O13 |
Molar mass | 881.98 g/mol g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
|
References
- Clinical trial number NCT01221870 for "Tesetaxel as First-line Therapy for Metastatic Breast Cancer" at ClinicalTrials.gov
- Evans, T.; Dobrila, R.; Berardi, R.; Sumpter, K.A.; Wall, L.R.; Oyama, R. (June 2006). "A phase II study of DJ-927 as second-line therapy in patients (pts) with advanced gastric cancer (GC) who have failed a 5-FU non taxane based regimen". Journal of Clinical Oncology.
- Clinical trial number NCT00080834 for "DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma" at ClinicalTrials.gov
- Clinical trial number NCT01315431 for "A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors" at ClinicalTrials.gov
- Shionoya, Motoko; Jimbo, Takeshi; Kitagawa, Mayumi; Soga, Tsunehiko; Tohgo, Akiko (2003). "DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo". Cancer Science. 94 (5): 459–466. doi:10.1111/j.1349-7006.2003.tb01465.x.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.